HighMark Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

HighMark Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10	Closed	-$3.92K	–	663
2025 Q3	$3.92K	Hold	10	–	–	﹤0.01%	428
2025 Q2	$4.45K	Sell	10 -1	-9%	-$461	﹤0.01%	409
2025 Q1	$5.33K	Hold	11	–	–	﹤0.01%	363
2024 Q4	$4.43K	Hold	11	–	–	﹤0.01%	390
2024 Q3	$5.12K	Sell	11 -11	-50%	-$5.28K	﹤0.01%	403
2024 Q2	$10.3K	Buy	22 +11	+100%	+$4.78K	0.01%	273
2024 Q1	$4.6K	Hold	11	–	–	﹤0.01%	386
2023 Q4	$4.48K	Sell	11 -4	-27%	-$1.48K	﹤0.01%	386
2023 Q3	$5.22K	Buy	15 +3	+25%	+$1.05K	﹤0.01%	346
2023 Q2	$0	Buy	+12	New	+$4.04K	﹤0.01%	619
2021 Q3	–	Sell	-19	Closed	-$5K	–	525
2021 Q2	$5K	Sell	19 -24	-56%	-$5.02K	﹤0.01%	379
2021 Q1	$9K	Buy	43 +2	+5%	+$439	0.01%	256
2020 Q4	$10K	Hold	41	–	–	0.01%	237
2020 Q3	$11K	Hold	41	–	–	0.01%	218
2020 Q2	$12K	Sell	41 -7	-15%	-$1.9K	0.01%	179
2020 Q1	$11K	Sell	48 -14	-23%	-$3.21K	0.01%	148
2019 Q4	$13K	Buy	+62	New	+$12.5K	0.01%	172

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

HighMark Wealth Management's VRTX Position: Q4 2025 in Review

HighMark Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 10 shares — an estimated $3.92K sold.

HighMark Wealth Management first reported a position in VRTX in Q4 2019 and held it in 17 quarters. The position peaked at $13K in Q4 2019. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

HighMark Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
HighMark Wealth Management sold 10 Vertex Pharmaceuticals shares in Q4 2025, an estimated $3.92K.
HighMark Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 17 quarters.
HighMark Wealth Management's Vertex Pharmaceuticals position peaked at $13K in Q4 2019.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on HighMark Wealth Management's 13F filing for Q4 2025, filed 5 Feb 2026.